Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Edwards Lifesciences
(NY:
EW
)
66.30
-1.06 (-1.57%)
Streaming Delayed Price
Updated: 2:15 PM EDT, Sep 24, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Edwards Lifesciences
< Previous
1
2
...
6
7
8
9
10
11
12
13
Next >
3 No-Brainer Medical Device Stocks to Buy Right Now
April 06, 2023
These companies have consistently delivered revenue and EPS gains.
Via
The Motley Fool
Benzinga's Top Ratings Upgrades, Downgrades For March 29, 2023
March 29, 2023
Via
Benzinga
The Latest Analyst Ratings for Edwards Lifesciences
March 29, 2023
Via
Benzinga
Looking Into Edwards Lifesciences's Recent Short Interest
March 15, 2023
Via
Benzinga
Expert Ratings for Edwards Lifesciences
March 08, 2023
Via
Benzinga
Edwards Lifesciences Stock Jumps After Beating Fourth-Quarter Views
January 31, 2023
The company expects full-year sales to grow 9%-12% in constant currency.
Via
Investor's Business Daily
Benzinga's Top Ratings Upgrades, Downgrades For March 8, 2023
March 08, 2023
Via
Benzinga
Interview With David Rolfe of Wedgewood Partners
February 17, 2023
Motley Fool analyst John Rotonti recently seized the opportunity to interview David Rolfe.
Via
The Motley Fool
Buy/Sell: Wall Street's Top 10 Stock Calls This Week - Saturday, Feb. 4
February 04, 2023
What has Wall Street been buzzing about this week? Here are the top 5 buy calls and the top 5 sell calls made by Wall Street’s best analysts during the week of Jan. 30 through Feb. 3.
Via
Talk Markets
Here's How Much $1000 Invested In Edwards Lifesciences 10 Years Ago Would Be Worth Today
January 31, 2023
Via
Benzinga
What 8 Analyst Ratings Have To Say About Edwards Lifesciences
January 30, 2023
Via
Benzinga
A Preview Of Edwards Lifesciences's Earnings
January 30, 2023
Via
Benzinga
Expert Ratings for Edwards Lifesciences
November 28, 2022
Via
Benzinga
15 Analysts Have This to Say About Edwards Lifesciences
November 28, 2022
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For February 6, 2023
February 06, 2023
Via
Benzinga
Edwards Lifesciences Q4 Earnings Beats Street Estimates, Expects Easing Of Macro Headwinds Later In 2023
February 01, 2023
Via
Benzinga
2 Top Dividend Growth Stocks to Buy in February
February 01, 2023
They don't offer the highest yields, but these strongly profitable businesses are poised to raise their payouts at a blistering pace.
Via
The Motley Fool
Earnings Scheduled For January 31, 2023
January 31, 2023
Companies Reporting Before The Bell • Biophytis (NASDAQ:BPTS) is projected to report earnings for its first quarter.
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For January 30, 2023
January 30, 2023
Via
Benzinga
Amazon To Rally Around 29%? Here Are 10 Other Analyst Forecasts For Monday
January 30, 2023
Barclays cut the price target for Amazon.com, Inc. (NASDAQ: AMZN) from $140 to $130. Barclays analyst Ross Sandler maintained an Overweight rating. Amazon shares fell 1.2% to $101.06 in pre-market...
Via
Benzinga
2 Smartest Tech Stocks to Buy in 2022 and Beyond
December 20, 2022
The tech space is still bursting with opportunities for long-term investors.
Via
The Motley Fool
Jim Cramer Recommends These 5 Healthcare Stocks For 2023: 'Biggest Winners Were Boring, Consistent Operators'
December 16, 2022
Prominent market commentator Jim Cramer has recommended five healthcare stocks which he believes should be on investors’ shopping list for 2023.
Via
Benzinga
JPMorgan To Rally Around 17%? Here Are 10 Other Price Target Changes For Tuesday
December 06, 2022
Via
Benzinga
Reata Pharmaceuticals To Jump 220%? Plus JP Morgan Predicts $51 For Las Vegas Sands
November 28, 2022
Goldman Sachs boosted the price target on Reata Pharmaceuticals, Inc. (NASDAQ: RETA) from $86 to $115. Goldman Sachs analyst Madhu Kumar maintained the stock with a Buy rating. Reata Pharmaceuticals...
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For December 6, 2022
December 06, 2022
Via
Benzinga
S&P 500 Component DexCom Set For Further Price, Earnings Growth
November 13, 2022
Glucose monitor maker DexCom surged 19% after its Q3 report, and shares are holding those gains. Wall Street sees more growth ahead in 2023.
Via
MarketBeat
Topics
Stocks
Exposures
US Equities
Benzinga's Top Ratings Upgrades, Downgrades For December 2, 2022
December 02, 2022
Via
Benzinga
Edwards Life Sciences Stock Disaster Could Be Your Bounty
November 07, 2022
Heart disease equipment maker Edwards Life Sciences (NYSE: EW) stock has fallen (-46%) on the year after a disastrous reaction to its Q3 2022 earnings report.
Via
MarketBeat
Topics
Death
Exposures
COVID-19
Death
Cramer's Take On This Stock That's Down 53% Year-To-Date: 'I Think Long-Term. I Don't Want To Own It'
November 03, 2022
On CNBC’s "Mad Money Lightning Round," Jim Cramer said Cerence Inc. (NASDAQ: CRNC) can fall to $13, $12 in a market like this. "If you can take that level of pain, you can absolutely buy it, because it...
Via
Benzinga
7 Stocks to Buy at the ‘Midterm Elections’ Bottom
October 31, 2022
With the market tending to react positively to midterm election cycles, now may be a time to consider certain stocks to buy.
Via
InvestorPlace
< Previous
1
2
...
6
7
8
9
10
11
12
13
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.